Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities
A technology of carboxypeptidase and substrate, which is applied in the field of new chromogenic substrate and its application in the determination of carboxypeptidase activity, and can solve the problems of long time and difficulty in automation of color development method
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0152] Synthesize a group of azoformyl compounds of the present invention
[0153] Table 1 below lists the chemical formulas of 8 preferred compounds among the compounds of formula (I) of the present invention. Their absorption spectra measured with a UV-visible spectrophotometer (UVIKON-KONTRON) are shown in FIG. 1 .
[0154] The synthesis of one of the compounds, compound 4 (MxPAFFR), is described in detail below. The procedure for the preparation of this compound described below is the same as for each of the other compounds, except for compound 5 (MxPAFFK), for which a complementary step of lysine deprotection is essential (see Reaction Scheme and Explanation).
[0155] Table 1:
[0156] Mode
[0157] Compound 1: 2,3-DMPAFFR
[0158]
[0159] 2,3-Dimethylphenylazoformylphenylalanylarginine
[0160] Compound 2: 2,4-DMPAFFR
[0161]
[0162] 2,4-Dimethylphenylazoformylphenylalanylarginine
[0163] Compound 3: 2,5-DMPAFFR
[0164]
[0165] 2,5-Dimethylphenylaz...
Embodiment 2
[0414] 1- Assay principle and main reagents used
[0415] TAFIa Enzyme Activity Assay Principle
[0416]
[0417]
[0418] 2-Example of the protocol for measuring TAFI activity according to the method of the present invention
[0419] a) The first mode of operation: the thrombin-thrombomodulin method
[0420] The test plasma sample was divided into two equal parts, one part was added with PIC (Calbiochem-Réf. 217359), and the other part was added with Hépès buffer.
[0421] The two aliquots were then treated identically according to the following principles:
[0422] TAFI activation
[0423] 150 μl of plasma diluted 1 / 20 in Hépès buffer (or 13 μg / ml of purified TAFI in Hépès buffer);
[0424] 10 µl PIC or H 2 O;
[0425] 5 minutes at room temperature;
[0426] 150 μl coagulation activator buffer;
[0427] 10 minutes at room temperature;
[0428] 100 μl PPACK + 100 μl MxPAFFR (substrate) (5 mM).
[0429] TAFI activity test
[0430] 30 minutes at room temperatur...
Embodiment 3
[0469] Establishing a Calibration Curve in the Thrombin-Thrombomodulin Method
[0470] under image 3 is a calibration curve established by spiking pure TAFI to TAFI-free plasma to obtain a TAFI concentration of 0-26 μg / ml.
[0471] The compound of formula I used was MxPAAFR at a concentration of 5 mM.
[0472] TAFIa concentration (μg / ml)
0
1.63
3.25
6.5
13
26
Measured ΔOD
0.168
0.217
0.273
0.399
0.624
0.995
[0473] Such as image 3 As shown, the calibration curve is linear over the concentration range studied. This fully covers the prescribed concentration range, ie, the concentration of TAFI in vivo of 5-15 μg / ml.
[0474] Thus, the methods of the invention can detect deficient and abnormally high levels of TAFI.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 